Affibody Medical announces outcome of rights issue

The outcome of the Rights Issue shows that 11,055,014 shares, corresponding to approximately 79 percent of the Rights Issue, have been subscribed with the support of subscription rights. In addition, 2,937,527 shares, corresponding to approximately 21 percent of the Rights Issue, have been subscribed without the support of subscription rights. Hence, the Rights Issue is fully subscribed.

Affibody’s main shareholder Patricia Industries, part of Investor AB, had via its subsidiary Duba AB committed to subscribe for its pro rata share, as well as any remaining shares not subscribed for by other shareholders. Duba AB will own approximately 85 percent of the shares in the Company, after the completion of the Rights Issue.

The Rights Issue will provide the Company with approximately SEK 120 million of new liquid funds before deduction of transaction costs. The remaining amount relates to conversion of shareholder loans, including accrued interest.

On January 20, 2026, Affibody announced that the board of directors had resolved on a rights issue of approximately SEK 307 million with authorisation from the general meeting held on May 27, 2025. Through the Rights Issue, the number of shares in Affibody will increase by 13,992,541, from 24,486,948 to 38,479,489 and the share capital will increase with SEK 69,962,705, from SEK 122,434,740 to SEK 192,397,445, corresponding to a dilution effect of approximately 36.4 percent of the total number of shares and votes in the Company.